CN103861041A - Traditional Chinese medicinal composition for treating acute and chronic rhinitis and preparation method thereof - Google Patents
Traditional Chinese medicinal composition for treating acute and chronic rhinitis and preparation method thereof Download PDFInfo
- Publication number
- CN103861041A CN103861041A CN201410113223.9A CN201410113223A CN103861041A CN 103861041 A CN103861041 A CN 103861041A CN 201410113223 A CN201410113223 A CN 201410113223A CN 103861041 A CN103861041 A CN 103861041A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- chronic rhinitis
- acute
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 87
- 206010039083 rhinitis Diseases 0.000 title claims abstract description 83
- 201000009240 nasopharyngitis Diseases 0.000 title claims abstract description 39
- 230000001154 acute effect Effects 0.000 title claims abstract description 38
- 201000009151 chronic rhinitis Diseases 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 121
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 11
- 239000002775 capsule Substances 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 18
- 241000628997 Flos Species 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 241000208966 Polygala Species 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 241000245240 Lonicera Species 0.000 claims description 2
- 241000545442 Radix Species 0.000 claims description 2
- 241000555682 Forsythia x intermedia Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 58
- 239000000126 substance Substances 0.000 abstract description 6
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 241001233914 Chelidonium majus Species 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 235000003392 Curcuma domestica Nutrition 0.000 abstract 1
- 241000218671 Ephedra Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 206010019851 Hepatotoxicity Diseases 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 241000234435 Lilium Species 0.000 abstract 1
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 241000913745 Spatholobus Species 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 230000007686 hepatotoxicity Effects 0.000 abstract 1
- 231100000304 hepatotoxicity Toxicity 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 235000013976 turmeric Nutrition 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 34
- 210000004369 blood Anatomy 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 22
- 210000004185 liver Anatomy 0.000 description 17
- 208000002193 Pain Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000036407 pain Effects 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 8
- 206010014025 Ear swelling Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 201000009890 sinusitis Diseases 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 241000555712 Forsythia Species 0.000 description 4
- 206010028748 Nasal obstruction Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 229960002179 ephedrine Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000004371 toothache Diseases 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 206010006002 Bone pain Diseases 0.000 description 3
- 241000345998 Calamus manan Species 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- -1 Phenylpropanoid Glycosides Chemical class 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 208000005946 Xerostomia Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000012950 rattan cane Nutrition 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000207834 Oleaceae Species 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 description 1
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 241001098038 Callerya cinerea Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241001111317 Chondrodendron tomentosum Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010052369 Encephalitis lethargica Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000576429 Forsythia suspensa Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 241000827798 Hemerocallis citrina Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 241000561703 Kadsura heteroclita Species 0.000 description 1
- 241001083838 Lardizabalaceae Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241000122904 Mucuna Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000158526 Nasalis Species 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000304447 Sempervivum tectorum Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 241000800405 Spatholobus suberectus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000009670 cang er zi wan Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000021551 crystal sugar Nutrition 0.000 description 1
- 229930195443 cynapanoside Natural products 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940090416 oxymetazoline nasal spray Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000001369 pituitary-adrenal system Anatomy 0.000 description 1
- 229960003764 polydatin Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Polymers O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000001944 turbinate Anatomy 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 description 1
- 229930001895 zingiberene Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicaments, relates to a traditional Chinese medicinal composition and a preparation method thereof, and in particular relates to a traditional Chinese medicinal composition for treating acute and chronic rhinitis and a preparation method thereof. Aiming at the existing technical defects of high hepatotoxicity and poor curative effect of a current chemical treatment medicament for treating acute and chronic rhinitis, the invention provides the traditional Chinese medicinal composition for treating or preventing acute and chronic rhinitis and the traditional Chinese medicinal composition comprises the following components in parts by weight: 10-50 parts of fructus forsythiae, 10-20 parts of safflower, 5-20 parts of turmeric, 5-15 parts of paniculate swallowwort root, 5-10 parts of raw rehmannia, 5-15 parts of lily, 5-15 parts of honeysuckle, 1-10 parts of poria, 5-15 parts of medlar, 9-15 parts of ephedra, 9-15 parts of ligusticum wallichii, 5-15 parts of angelica root, 0.2-9 parts of radix ophiopogonis, 5.5-15 parts of polygonum cuspidatum, 6-9 parts of suberect spatholobus stem and 10-15 parts of liquorice. The traditional Chinese medicinal composition has a good treatment effect on the aspect of treating or preventing acute and chronic rhinitis, has low side effects, and has a remarkable clinical popularization value.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of Chinese medicine composition for the treatment of acute and chronic rhinitis and preparation method thereof.
Background technology
Rhinitis is due to virus, courses of infection, or the nasal membrane and the submucosal chronic inflammatory disease that under the effect of stimulus object, cause.Clinical manifestation is nasal membrane swelling, secretions increase, headache, giddy etc.More than the course of disease continues the several months or repeatedly, show effect.Rhinitis causes producing too much mucus, conventionally cause the symptom such as watery nasal discharge, nasal obstruction, cause mucosa, tela submucosa, the even limitation of periosteum and bone or diffusivity proliferation of fibrous tissue, plump, concha nasalis inferior is the most obvious, and its front and back end can become nodositas with lower edge, Fructus Mori shape or lobulated plumpness, also can there is hypertrophy, plumpness or Polypoid changes in middle nasal concha front end and nasal septal membrane.The research nearest by the U.S. shows, exceeding 5,000 ten thousand Americans is rhinitis patients.Do not treat for a long time, rhinitis also can affect people's sleep quality, audition and learning capacity.Also can cause antibacterial and be stayed in for a long time nasal cavity amount reproduction, and then cause flu.Flu inflammation long-term existence increases the weight of rhinitis symptom.Rhinitis Chinese medicine belongs to nasal sinusitis category.Its etiology and pathogenesis mostly is experiences the heresy of wind heat or the heresy of wind and cold enters inner heat-transformation, and the turbid tears resistance of pyretic toxicity is closed nose key and formed.Chronic person is many because of deficiency of the spleen and lung, and insufficiency of lung-QI is to weakened defensive QI, susceptible exopathogen.Insufficiency of the spleen transformation failure of spleen, phlegm-damp is detained, tired knot nose key, contamination sinus mucosa forms nasal sinusitis.At present, the Western medicine for the treatment of acute and chronic rhinitis is a lot, but most drug therapeutic effect is poor, and treats in addition the shortcomings such as high, side effect is large, even affects patient health when serious.Clinical treatment of rhinitis is main mainly with intranasal Decongestant (oxymetazoline nasal spray ephedrine nasal drop), glucocorticoid, side effect is to produce rebound phenomenon, even there is even more serious nasal obstruction, the hypertrophy that long-term rhinitis is produced, plump effect is not good enough.And Chinese medicine rhinitis curative effect is reliable, toxic and side effects is little, has broad prospects.But mostly adopt Fructus Xanthii Flos Magnoliae etc., feature is to have certain drug toxicity, can not long-term taking, and also long-term effect is undesirable, and large for nasal drop local irritation, curative effect is of short duration.The object of the invention is to provide a kind of effect comprehensively, the Chinese medicine composition of the treatment acute and chronic rhinitis that clinical effectiveness is good.
Make a general survey of the research direction of world's new drug, be mainly single chemicals and preparations thereof of research and development the eighties in the past, starts to develop biotechnology and natural medicinal plants after the eighties, and drug research direction is tending towards multiformity.In conjunction with modern Chinese medicine theory of development, from improving the angle of curative effect of medication, reduction side effect, through Chinese medicine ingredients being screened to the preparation that extraction and/or compatibility make, its side effect is little, safe, has the advantage that chemical synthetic drug can not be compared.
Summary of the invention
Large in order to overcome existing acute and chronic rhinitis chemotherapeutic agent toxic and side effects, acute and chronic rhinitis therapeutic effect is difficult to lasting prior art deficiency, the invention provides a kind of Chinese medicine composition for the treatment of acute and chronic rhinitis, this Chinese medicine composition good effect, side effect is little, it is mainly made by following raw material: Fructus Forsythiae 10-50 part, Flos Carthami 10-20 part, Rhizoma Curcumae Longae 5-20 part, Radix Cynanchi Paniculati 5-15 part, Radix Rehmanniae 5-10 part, Bulbus Lilii 5-15 part, Flos Lonicerae 5-15 part, Poria 1-10 part, Fructus Lycii 5-15 part, Herba Ephedrae 9-15 part, Rhizoma Chuanxiong 9-15 part, Radix Angelicae Dahuricae 5-15 part, Radix Ophiopogonis 0.2-9 part, Rhizoma Polygoni Cuspidati 5.5-15 part, Caulis Spatholobi 6-9 part, Radix Glycyrrhizae 10-15 part.
Fructus Forsythiae is one of conventional Chinese medicine of Chinese Clinical, has another name called that Hemerocallis citrina Baroni bar, Fructus Forsythiae, green grass or young crops stick up, fall to sticking up, Huang Qidan etc.Fructus Forsythiae recording of Pharmacopoeia of the People's Republic of China version in 2005 is Oleaceae (Oleaceae) Forsythia (Forsythia) plant Fructus Forsythiae (Forsythia suspensa(Thunb.) Vahl) dry fruit, fruit just ripe still gathering when band is green is called green grass or young crops and sticks up, and gathers to be called always and stick up when the well-done color jaundice of fruit.The pharmacological action such as that Fructus Forsythiae has is antibacterial, heart tonifying, diuresis, town are told, the diseases such as the conventional acute anemopyretic cold of forsythia fruit for treating, carbuncle sore tumefacting virus, tuberculous lymphadenitis, urinary tract infection are the primary raw material of the Chinese medicine preparation such as two chuanxiong rhizome oral liquid, two Rhizoma Chuanxiong power injection, QINGRE JIEDU KOUFUYE, the careless antipyretic oral liquid of company, flos ionicerae and fructus forsythiae infusion for detoxication.
Flos Carthami main chemical compositions comprises saffloside, the awake glycosides of Flos Carthami, Flos Carthami polysaccharide, Palmic acid, cinnamic acid, there is vasodilative effect, can reduce coronary resistance, increase coronary artery blood flow, improve Nutritional myocardium blood flow amount, have anti-blood and the anti-thrombosis function of doubting, can excited uterus, low dose makes uterus that rhythmicity contraction occur, and heavy dose makes the love of uterus muscle convulsion, can reduce the blood lipid level such as cholesterol in serum and triglyceride.Its function comprises: promoting blood circulation to remove obstruction in the collateral, and eliminating stasis to stop pain, for amenorrhea, dysmenorrhea, lochia, WEIJIA mass in the abdomen, injury from falling down, skin ulcer pain swells and ache.
Rhizoma Curcumae Longae: medicinal its rhizome, bitter in the mouth is pungent, warm in nature, returns liver, spleen two warps.Main component such as, containing volatile oil, Rhizoma Curcumae Longae essence, dehydrogenation Rhizoma Curcumae Longae essence, zingiberene etc.Rhizoma Curcumae Longae can be declared the gas in logical blood, the capable and blood of gas is not stopped up stagnant, and has effect of inducing menstruation to relieve menalgia.Rhizoma Curcumae Longae can increase bile and forms and secrete, and cholic acid and the cholesterol in feces, drained are increased.A little less than although Rhizoma Curcumae Longae promotes the effect of bile secretion, more lasting.Rhizoma Curcumae Longae can also increase fibrinous lytic activity, has antithrombotic effect.Find according to pharmacological research, Rhizoma Curcumae Longae has the effect in excited uterus, can make uterine contraction, and pregnant woman is cautious use of.
Doctors and patients portion otch greatly, part vertebral plate and articular process excision, or the capable discectomy of inter-laminar space.The main chemical compositions of Radix Cynanchi Paniculati comprises C21 steroid, cynapanoside, Bai wei glycosides, have analgesic activity, sedation, can reduce coronary artery blood flow, improve myocardial metabolism, alleviate myocardial ischemia, has effect for reducing blood fat, and prevention of arterial is atherosis, to staphylococcus aureus, escherichia coli, bacterium sonnei, bacillus pyocyaneus has inhibitory action.Its function comprises: sedation-analgesia, wet removing toxic substances, rheumatic arthralgia, headache, toothache, traumatic injury, dizziness, skin eczema, snake bite and insect sting.The traditional Chinese medical science thinks that Bulbus Lilii has the effect of nourishing the lung to arrest cough, clearing away heart-fire for tranquillization, and especially fresh Bulbus Lilii is more sweet delicious.The people that Bulbus Lilii is particularly suitable for foster lung, nourishing the stomach eats, such as the patient of chronic cough, pulmonary tuberculosis, aphtha of the mouth and tongue, xerostomia, halitosis.Bulbus Lilii not only has good nutritious tonifying effect, and for the patient such as deficient syndrome, tuberculosis, neurosis is of great advantage after being ill, various cancers is had to good curative effect.Aspect the prevention and treatment of tumor, Bulbus Lilii is used for treating pulmonary carcinoma, nasopharyngeal carcinoma, skin carcinoma etc.When the symptoms such as, xerostomia weak in the body void that above-mentioned cancer is carried out occurring after radiotherapy, vexed, dry cough expectorant, cook congee together with Semen oryzae sativae with fresh Bulbus Lilii, after calling in again appropriate crystal sugar or Mel, eat, to the reaction of health invigorating, anticancer growth, alleviation radiotherapy, there is good effect.For another example, fresh Bulbus Lilii and white sugar are smash to deposited affected part in right amount altogether,, infiltration person hemorrhage to skin carcinoma ulceration also has certain therapeutical effect.
Flos Lonicerae is cold in nature, and sweet in the mouth enters lung, the heart, stomach warp, has effect of heat-clearing and toxic substances removing, antiinflammatory, tonify deficiency treatment wind, cures mainly disease under distension, epidemic febrile disease heating, the diseases such as pyretic toxicity carbuncle and ulcer and tumor.The diseases such as it is dizzy for giddy, xerostomia is done yearningly, hyperhidrosis is unhappy, enteritis, bacillary dysentery, measles, pneumonia, encephalitis b, epidemic encephalitis, acute mastitis, septicemia, appendicitis, skin infection, carbuncle furuncle, erysipelas, parotitis, suppurative tonsillitis all have certain curative effect.Flos Lonicerae tea has unique weight losing function simultaneously, can also suppress and the pathogen of killing bottleneck throat, and old man and child are had to infection effect.So, often take Flos Lonicerae immersion or decoct and be conducive to wind-fire conjunctival congestion, laryngopharynx swelling and pain, obesity, the hypertensive treatment of liver-heat disease regulating liver-QI pattern of fever and rehabilitation.
Poria, is commonly called as Poria, Song Ling, Poria, and for colonizing in the fungi plant on pinaster root, shape is as Rhizoma Dioscoreae esculentae, crust pitchy, the inside white or pink.Ancients claim that Poria is " god medicine " at 4 o'clock, because its effect is very extensive, regardless of the four seasons, by it and various compatibility of drugs, no matter cold, temperature, wind, all diseases that wets can be brought into play its unique effects.Poria sweet in the mouth, light, property are flat, be used as medicine there is promoting diuresis to eliminate damp pathogen, the function of strengthening the spleen stomach function regulating, mind tranquilizing and the heart calming.Modern medicine study: Poria energy enhancing human body immunity function, pachyman has obvious antitumor and protects the liver dirty effect.
Fructus Lycii (formal name used at school: Lycium chinense) is the multi-branched shrub plant of Solanaceae Lycium, and high 0.5-1 rice, can reach more than 2 meters when cultivation.All there is distribution both at home and abroad.Fructus Lycii whole body is precious, and bright Li Shizhen (1518-1593 A.D.) Compendium of Material Medica is recorded: " spring is adopted Folium Lycii, name day essence grass; Summer picks flowers, name Sempervivum tectorum; Qiu Caizi, name Fructus Lycii; Dong Caigen, name Cortex Lycii ".Fructus Lycii tender leaf also claims Fructus Lycii head, edible or make Fructus Lycii tea.Modern study, Fructus Lycii has the blood glucose of reduction, lipotropy, and can antiatherogenic effect.
Herba Ephedrae has diaphoresis cold expelling, depressed lung-energy dispersing, effect of inducing diuresis to remove edema.Clinical in anemofrigid cold, uncomfortable in chest breathing with cough, edema due to wind pathogen edema; Bronchial asthma.Honey Herba Ephedrae nourishing the lung to arrest cough.Be used for showing disease and separate, the diseases such as asthma and cough.Modern pharmacology demonstration, ephedrine has antifatigue effect to skeletal muscle, can promote by the conduction between the neuromuscular that curare suppressed, and can be used for the treatment of myasthenia gravis; Also can cause hyperglycemia, but it acts on compared with weak and non-constant.Ephedrine and Herba Ephedrae total alkaloids all do not show perspiration to normal and heating cat, and in the ordinary course of things, ephedrine can not bring out perspiration to people.
The pungent temperature of Rhizoma Chuanxiong is fragrant dry, walks and does not keep, can go loose, the up top, mountain peak that reaches; Enter again blood system, the descending sea of blood that reaches.Blood circulation promoting and blood stasis dispelling effect is extensive, the various diseases of suitable stagnation of blood stasis; Wind-expelling pain-stopping, effectiveness is excellent, can control the diseases such as wind syndrome of head headache, rheumatic arthralgia.It is the gas medicine in blood that former times people calls Rhizoma Chuanxiong, nearly says the functions such as pungent loose, the resolving depression of its residence, sensible, pain relieving.The pungent temperature rise of this product is loose, and all hyperactivity of YANG due to deficiency of YIN and excessive rising of liver-YANG person should not apply; Menorrhagia, anemia of pregnant woman also avoid use.
The Radix Angelicae Dahuricae, warm in nature, acrid in the mouth is micro-sweet, has expelling wind and removing dampness; Logical surreptitiously pain relieving; Effect of detumescence and apocenosis.Main headache due to common cold; Supraorbital bone pain; Toothache; Nasal obstruction; Nasal sinusitis; Domination of damp pathogen chronic diarrhea; Women leucorrhea; Ulcer sores; Venom.Clinical in headache due to common cold, supraorbital bone pain, nasal obstruction, nasal sinusitis, toothache, leucorrhea, skin infection swells and ache.Also can be used for the cold expelling that induces sweat, wind-expelling pain-stopping, clearing the nasal passage, dampness leukorrhagia stopping, detumescence and apocenosis.Control headache, supraorbital bone pain, toothache, nasal sinusitis, cold-damp stomachache, hemorrhoidal hamorrhage anal fistula, leucorrhea with red and white discharge, ulcer sores, skin pruritus due to dryness, scabies.Rhizoma Atractylodis have drying damp and strengthening spleen, expelling wind and cold, and effect of improving eyesight, for dampness taste, distension and fullness in the abdomen, cold-damp leucorrhea, damp-warm diseases and damp invasion of lower energizer, foot swelling and pain in knee, flaccidity are soft unable.Control dampness taste, and see the thick disease such as turbid of distension and fullness in the abdomen, inappetence, fatigue and weakness, white and greasy fur, the compatibilities such as normal and Cortex Magnoliae Officinalis, Pericarpium Citri Reticulatae are applied.
Radix Ophiopogonis, has another name called Radix Ophiopogonis, is Liliaceae Ophiopogon plant.Be used as medicine Radix Ophiopogonis with tuber.Nature,taste and action: sweet, micro-hardship, cool, Yin-nourishing and body fluid promoting, nourishing the lung to arrest cough, relieving restlessness clears away heart-fire.Cure mainly consumption of body fluid caused by febrile disease, vexed, thirsty, dry pharynx lung-heat, cough, pulmonary tuberculosis.
Rhizoma Polygoni Cuspidati: medicinal its root, slightly warm in nature, tool promoting blood circulation to restore menstrual flow, dampness removing function, tradition is used for the treatment of rheumatism, arthralgia pain, jaundice, amenorrhea, dysmenorrhea etc.Prove according to modern pharmacological research, Rhizoma Polygoni Cuspidati is containing anthraquinone analog compound and flavonoid Multiple components, can extract the polydatin etc. with component for reducing blood fat in acting in accordance with YIN YANG changes in four seasons stem.About experiment showed, that Rhizoma Polygoni Cuspidati has the effect that reduces cholesterol and triglyceride.
Caulis Spatholobi: be the rattan of pulse family Climbing Plant spatholobus suberectus, Millettia dielsiana, evergreen mucuna etc.Someone thinks that this medicine comes from supplementary Amplifications of the Compendium of Materia Medica, describes with different now but examine its plant.Its name that really name conforms to reality comes from the Wang Ang of Qing Dynasty essentials of Matea Medica, and other this agrostology is also loaded with the another name such as " Radix seu Caulis Verntilaginis Leiocarpae ", " Caulis seu Radix Schisandrae Henryi ".Some area as northeast, northwest, Central-South the rattan of Lardizabalaceae liana Caulis Sargentodoxae (being Caulis Sargentodoxae, Caulis Sargentodoxae, aftermentioned) is used as to Caulis Spatholobi, Caulis Spatholobi is used as the rattan of Magnoliacea plant Kadsura heteroclita and middle Fructus Schisandrae Chinensis in Yunnan.Just logical Caulis Spatholobi main product Guangxi, Guangdong, property bitter but sweet flavor temperature, return Liver Channel, there is promoting the circulation of blood to enrich blood, regulating menstruation, the effects such as relaxing muscles and tendons and activating QI and blood in the collateral, can treat that the gynaecopathia such as menoxenia, blockage of menstruation, dysmenorrhea, blood deficiency amenorrhea and rheumatic arthralgia, numb hand and foot, limbs are weak and limp, blood deficiency dull yellowish colored skin etc., and controlling leukopenia also has certain curative effect.
Chinese medicine composition of the present invention take except long-pending numbness, dispersing wind and cold, wind-damp dispelling, bone and muscle strengthening are as main standard, has significant antiinflammatory, analgesia and activating blood circulation to dissipate blood stasis effect after Chinese medicine composition combination of the present invention on Chinese medicinal components is selected.The present invention has carried out preferably the parts by weight of above-mentioned all taste Chinese medicine, and preferred condition is the enhancing of medicine to acute and chronic rhinitis therapeutic effect after drug matching is used.As a preferred embodiment of the present invention, Chinese medicine composition of the present invention is mainly made by the raw material of following weight portion: 30 parts of Fructus Forsythiaes, 15 parts, Flos Carthami, 15 parts, Rhizoma Curcumae Longae, 10 parts of Radix Cynanchi Paniculatis, 8 parts, the Radix Rehmanniae, 10 parts of Bulbus Liliies, 10 parts of Flos Loniceraes, 6 parts, Poria, 10 parts of Fructus Lyciis, 12 parts, Herba Ephedrae, 12 parts of Rhizoma Chuanxiongs, 10 parts of the Radixs Angelicae Dahuricae, 5.5 parts of Radix Ophiopogonis, 10 parts of Rhizoma Polygoni Cuspidati, 8 parts of Caulis Spatholobis, 12 parts, Radix Glycyrrhizae.
Preferably, Chinese medicine composition of the present invention also further contains 7 parts of the Radix Aucklandiae, 5 parts of the Cortexs Eucommiae, 9 parts of Radix Polygalaes.Radix Aucklandiae acrid in the mouth, hardship, warm in nature; Return spleen, stomach, liver, large intestine channel, fragrance row is loose, can rise and can fall.It has following effect: promoting the circulation of QI to relieve pain, vomit for abdominal distention, lack of appetite due to stagnation of QI in spleen and stomach; Regulate the flow of vital energy soothing the liver, the hypochondriac pain causing for QI stagnation of the liver and galibladder.Spleen invigorating disappears stagnant, the stagnant gas of adjustable gastrointestinal.Treatment stomachache, diarrhoea, tenesmus.The main chemical compositions of the Cortex Eucommiae comprises multiple lignanoid, Phenylpropanoid Glycosides and iridoid, there is hypotensive activity, reuse and can produce toleration, can excited pituitary adrenal system function, improve the phagocytic function of peritoneal macrophage, can resist the immunosuppressive action of hydrocortisone.Its function comprises: invigorating the liver and kidney, and bone and muscle strengthening, antiabortive, lumbago due to renal deficiency, muscles and bones is unable, and leak blood pregnant morning, frequent fetal movement, hypertension.Radix Polygalae is conventional Chinese medicine, be recorded in the earliest Shennong's Herbal, classify as top grade, and be regarded as support life key medicine, warm in nature, bitter in the mouth, pungent, the function of there is the Fructus Alpiniae Oxyphyllae of calming the nerves, eliminate the phlegm, subsiding a swelling, the insomnia and dreamful sleep causing for disarmony between the heart and kidney, forgetful palpitation with fear, staring spells, expectoration is not well, sore swollen toxin, breast swell and pain.
In order to express better Chinese medicine composition of the present invention, Chinese medicine composition of the present invention can be prepared into conventional clinically dosage form.Such as, the preparations such as powderous preparations, powder, pill, sublimed preparation, unguentum, granule, oral liquid, syrup, tablet, capsule.Preferably, Chinese medicine composition of the present invention is prepared into powder, water preparation, tablet or capsule according to conventional preparation technology.
The present invention also provides a kind of preparation method of Chinese medicine composition described above, it mainly comprises following step: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, doubly adding volumetric concentration according to the 4-9 of coarse powder gross weight is the alcoholic solution of 40%-95%, reflux, extract, three times, return time is 2-5h, filters, filtrate recycling ethanol, cold filtration, washes with water, after being dried, obtains Chinese medical concrete; Those skilled in the art can be at the technical conventional Chinese medicine pharmaceutical dosage form clinically for preparing of this preparation method, as tablet, capsule etc.
The present invention also asks to protect the purposes of above-mentioned Chinese medicine composition in preparation treatment acute and chronic rhinitis medicine.Pharmaceutical composition of the present invention, in the time for the treatment of acute and chronic rhinitis, demonstrates significant anti-inflammatory and antalgic, activating blood circulation to dissipate blood stasis activity.Drug effect embodiment 19 of the present invention shows, with model group comparison, the low middle Senior Three of a Chinese medicine composition of the present invention dosage group all can significantly reduce dimethylbenzene induced mice ear swelling value (
p< 0.01), show that Chinese medicine composition of the present invention has the effect of the mice ear of remarkable inhibition dimethylbenzene induction, and there is significant dose-effect relationship in its reduction effect to ear swelling.Under same experiment condition, positive control drug Biyan Ning capsule group also significantly reduce ear swelling value (
p< 0.05), but its antiphlogistic effects is obviously not as good as Chinese medicine composition of the present invention.Drug effect embodiment 20 of the present invention shows, mice licks foot response latency time showing, with model group comparison, after administration after 1h and 2h, all be greater than model group the incubation period that the mice of each administration group of Chinese medicine composition of the present invention is added foot reaction, there is dose-dependence, and be significantly greater than the incubation period of high dose group model group (
p< 0.05).Illustrate this Chinese medicine composition of the present invention can extend mice to hot plate stimulate add the sufficient response latency, have certain analgesic activity.Under same experiment condition, positive control drug Tongqiao Biyan capsules group (
p< 0.05) and Biyan Ning capsule group (1h,
p< 0.05; 2h,
p< 0.01) also significant prolongation mice incubation period of adding foot reaction, have certain analgesic activity.Drug effect embodiment 21 of the present invention shows, model group and normal control comparison, the low cut index of whole blood, erythrocyte aggregation index, Casson viscosity and plasma viscosity all have significantly and increase (
p< 0.05).With model group comparison, basic, normal, high each dosage group of the Chinese medicine composition of the present invention all remarkable or utmost point has reduced the low cut index of whole blood, erythrocyte aggregation index, Casson viscosity and plasma viscosity significantly, reduction amplitude amount effect relationship, wherein high dose there were significant differences (
p< 0.05).Under same experiment condition, positive control drug Tongqiao Biyan capsules group has also reduced the high cut index of whole blood, the low cut index of whole blood, erythrocyte aggregation index, but it improves effect all not as good as Chinese medicine composition of the present invention to hemorheology index.The result statistics of liver index shows, model group and normal control comparison, and liver index significantly increases.And with model group comparison, basic, normal, high each dosage group of Chinese medicine composition of the present invention significantly reduced liver index (
p< 0.01), positive control drug Tongqiao Biyan capsules and Chinese medicine composition of the present invention Chinese medicine composition high dose group of the present invention can reduce significantly liver index (
p< 0.05), but effect is not as good as Chinese medicine composition of the present invention.Embodiment 22 results show, Chinese medicine composition of the present invention all has good fungistatic effect to most pathogenic entero becteria, this shows that Chinese medicine composition of the present invention all has significant therapeutic effect for the acute and chronic rhinitis of various bacteria or fungus initiation, can play to infectious acute and chronic rhinitis the effect for the treatment of both the principal and secondary aspects of a disease.And more estimable, in Chinese medicine composition of the present invention, contain plurality of active ingredients, during for acute and chronic rhinitis treatment of infection, target spot is many, be difficult for produce drug resistance, be significantly better than existing clinical in widely used antibiotics.
In a word, pharmaceutical composition of the present invention, aspect treatment acute and chronic rhinitis, compared with prior art has following advantage:
1) compared with positive control drug Tongqiao Biyan capsules or Biyan Ning capsule, pharmaceutical composition Chinese medicine composition of the present invention is not only more remarkable at antiinflammatory and ease pain, and aspect activating blood circulation to dissipate blood stasis, be also significantly better than positive drug, this shows that the present composition has significant synergism in acute and chronic rhinitis treatment, not only can significantly improve the symptom of acute and chronic rhinitis, can also delay the development of acute and chronic rhinitis, contribute to acute and chronic rhinitis patient's recovery from illness process;
2) compared with the chemotherapeutic agent of current treatment acute and chronic rhinitis, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, untoward reaction and side effect significantly reduce, particularly it does not produce any destruction for intestinal mucosa, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, has significantly improved acute and chronic rhinitis patient's compliance, and has improved patient's quality of life;
3) existing antibiotic medicine acute and chronic rhinitis initial stage therapeutic effect still can, but along with obvious drug resistance problem all appears in the prolongation for the treatment of time, its therapeutic effect for acute and chronic rhinitis declines.In Chinese medicine composition of the present invention, contain multi-medicament component, action target spot is numerous, has effectively solved the Commpensation And Adaptation of acute and chronic rhinitis medicine, its to the therapeutic effect of acute and chronic rhinitis not because for the treatment of time extend decline.
The specific embodiment
Further describe the present invention by specific embodiment below, the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, change, combination or replacement that the present invention is carried out, be apparent for a person skilled in the art, and be included within the scope of the present invention.
part I Chinese medicinal composition preparation of the present invention, preparation and using method thereof
embodiment 1-6 Chinese medicine composition composition powders
table 1 Chinese medicine composition composition powders prescription of the present invention
Embodiment 1 preparation method: get each medical material in compositions, grind to form powdery according to common process, cross 100 mesh sieves, little fire drying is for subsequent use, obtains powder.When use, with directly taking after mixing it with water after water dissolution.Embodiment 2-6 preparation method is with embodiment 1.
embodiment 7-12 Chinese medicine composition water preparation
table 2 Chinese medicine composition water preparation prescription of the present invention
Embodiment 7 preparation methoies: get each medical material in prescription, according to conventional decocting for Chinese herbal medicine technological operation, filtering medicinal residues and get final product.When this water preparation is treated for acute and chronic rhinitis, take 2-3 every day.Embodiment 8-12 preparation method and using method are with embodiment 7.
embodiment 13-18 Chinese medicine composition tablet/capsule of the present invention
table 3 Chinese medicine composition tablet of the present invention/capsule prescription
Embodiment 13 preparation technologies: each traditional Chinese medicine powder of getting recipe quantity is broken into coarse powder, adding volumetric concentration according to 5 times of coarse powder gross weight is 80% alcoholic solution, reflux, extract, three times, the each 3h of return time, filters filtrate recycling ethanol, cold filtration, washes with water, after being dried, obtains Chinese medical concrete; Chinese medical concrete drying, pulverizing are made to dried cream powder, add conventional adjunct ingredient to utilize prior art to be prepared into tablet or capsule.
Embodiment 14-18 preparation technology is with embodiment 13.
part II Chinese medicine composition pharmacodynamic study of the present invention
embodiment 19 Chinese medicine composition xylol of the present invention causes the impact of mice ear
Get 72 of healthy ICR mices, ♀ ♂ half and half, divide 6 groups, 12/group, be model group, Tongqiao Biyan capsules (Chuan great West China, Sichuan Pharmaceutical, lower same), Biyan Ning capsule group (production of Quanzhou, Fujian Province Luo Shangshan pharmaceutical factory), Chinese medicine composition of the present invention (making by Chinese medicine composition prescription and preparation technology described in embodiment 1) low dose group, middle dosage group and high dose group.1 time/d of every ig administration; Administration 14 d, 60 min after last medicine, mouse right ear is evenly smeared dimethylbenzene 0.03 mL/ and is only caused swollenly, cuts ears and beat auricle and weigh after 2h, calculates ear swelling value (mg).Swelling value=auris dextra weight-left ear weight.
Result show, with model group comparison, the low middle Senior Three of a Chinese medicine composition of the present invention dosage group all can significantly reduce dimethylbenzene induced mice ear swelling value (
p< 0.01), show that Chinese medicine composition of the present invention has the effect of the mice ear of remarkable inhibition dimethylbenzene induction, and there is significant dose-effect relationship in its reduction effect to ear swelling.Under same experiment condition, positive control drug Biyan Ning capsule group also significantly reduce ear swelling value (
p< 0.05), but its antiphlogistic effects is obviously not as good as Chinese medicine composition of the present invention.
the impact of table 4 Chinese medicine composition xylol of the present invention induced mice ear swelling (
)
Note: with model group comparison, *
p< 0.05, * *
p< 0.01.
the impact of embodiment 20 Chinese medicine composition of the present invention on mice hot-plate analgesia
1 mice hot plate pain model is made
Body weight 20g left and right female mice is placed on hot plate dolorimeter, (licking metapedes time < 5s or > 30s throws aside to screen 90 of qualified ♀ mices, scald for preventing foot, also should establish deadline, be generally 60s), the incubation period of adding metapedes reaction take mice is as threshold of pain index, get 72 jennies, be divided into 6 groups, 12/group, it is model group, Tongqiao Biyan capsules, Biyan Ning capsule group, Chinese medicine composition of the present invention (making by Chinese medicine composition prescription and preparation technology described in embodiment 1) low dose group, middle dosage group and high dose group.Each group is gastric infusion, and 1 times/day, dosage is as shown in table 10, after successive administration 14d, and the time that after mensuration last medicine, 60 min, 120 min add foot reaction.
chinese medicine composition of the present invention is on licking the impact of foot response latency in the experiment of mice hot-plate analgesia
Mice licks foot response latency time showing, with model group comparison, after administration after 1h and 2h, be all greater than model group the incubation period that the mice of each administration group of Chinese medicine composition of the present invention is added foot reaction, there is dose-dependence, and be significantly greater than the incubation period of high dose group model group (
p< 0.05).Illustrate this Chinese medicine composition of the present invention can extend mice to hot plate stimulate add the sufficient response latency, have certain analgesic activity.Under same experiment condition, positive control drug Tongqiao Biyan capsules group (
p< 0.05) and Biyan Ning capsule group (1h,
p< 0.05; 2h,
p< 0.01) also significant prolongation mice incubation period of adding foot reaction, have certain analgesic activity.The results are shown in Table 5.
table 5 mice lick foot response latency timetable (
)
Note: with model group comparison, *
p< 0.05, * *
p< 0.01.
the improvement effect of embodiment 21 Chinese medicine composition of the present invention to rat blood stasis models
Get healthy SD rat, body weight 180-200g, 70, male and female half and half, be divided at random 7 groups by body weight: basic, normal, high group of Normal group, model group, Tongqiao Biyan capsules group, Biyan Ning capsule group and Chinese medicine composition of the present invention (making by Chinese medicine composition prescription and preparation technology described in embodiment 1), 10 every group.Gastric infusion, successive administration 14 days, Normal group and model group are to 0.5%CMC, and all the other give corresponding medicine, and dosage is as shown in table 14.Administration the 13rd day, 14 days, except Normal group, all the other treated animals are pressed 1mg/Kg subcutaneous injection adrenalin hydrochloride, and 2 times/day, interval 4h, after injection, 2h puts animal in 4 ℃ of frozen water 15min for the first time.Administration is got 4-5ml blood anticoagulant heparin on the 15th day and is measured blood rheology parameter, gets the liver conversion organ coefficient of weighing.
Result shows, model group and normal control comparison, the low cut index of whole blood, erythrocyte aggregation index, Casson viscosity and plasma viscosity all have significantly and increase (
p< 0.05).With model group comparison, basic, normal, high each dosage group of the Chinese medicine composition of the present invention all remarkable or utmost point has reduced the low cut index of whole blood, erythrocyte aggregation index, Casson viscosity and plasma viscosity significantly, reduction amplitude amount effect relationship, wherein high dose there were significant differences (
p< 0.05).Under same experiment condition, positive control drug Tongqiao Biyan capsules group and Biyan Ning capsule group have also reduced the high cut index of whole blood, the low cut index of whole blood, erythrocyte aggregation index, but it improves effect all not as good as Chinese medicine composition of the present invention to hemorheology index.The result statistics of liver index shows, model group and normal control comparison, and liver index significantly increases.And with model group comparison, basic, normal, high each dosage group of Chinese medicine composition of the present invention significantly reduced liver index (
p< 0.01), positive control drug Tongqiao Biyan capsules and Chinese medicine composition of the present invention Chinese medicine composition high dose group of the present invention can reduce significantly liver index (
p< 0.05), but effect is not as good as Chinese medicine composition of the present invention.
table 6 Chinese medicine composition of the present invention on rat blood stasis models blood flow become impact (
)
Note: with normal control comparison, #
p< 0.05, ##
p< 0.01; With model group comparison, *
p< 0.05, * *
p< 0.01.
the impact of table 7 Chinese medicine composition of the present invention on rat blood stasis models liver coefficient (
)
Note: with normal control comparison, ##
p< 0.01; With model group comparison, *
p< 0.05, * *
p< 0.01.
Claims (7)
1. treat a Chinese medicine composition for acute and chronic rhinitis, it is characterized in that it is mainly made by the raw material of following weight portion:
Fructus Forsythiae 10-50 part, Flos Carthami 10-20 part, Rhizoma Curcumae Longae 5-20 part, Radix Cynanchi Paniculati 5-15 part, Radix Rehmanniae 5-10 part, Bulbus Lilii 5-15 part, Flos Lonicerae 5-15 part, Poria 1-10 part, Fructus Lycii 5-15 part, Herba Ephedrae 9-15 part, Rhizoma Chuanxiong 9-15 part, Radix Angelicae Dahuricae 5-15 part, Radix Ophiopogonis 0.2-9 part, Rhizoma Polygoni Cuspidati 5.5-15 part, Caulis Spatholobi 6-9 part, Radix Glycyrrhizae 10-15 part.
2. the Chinese medicine composition for the treatment of acute and chronic rhinitis as claimed in claim 2, is characterized in that: described Chinese medicine composition also contains the raw material of following weight portion: 7 parts of the Radix Aucklandiae, 9 parts of 5 parts of the Cortexs Eucommiae and Radix Polygalaes.
3. the Chinese medicine composition for the treatment of acute and chronic rhinitis as claimed in claim 1, is characterized in that it is mainly made by the raw material of following weight portion: 30 parts of Fructus Forsythiaes, 15 parts, Flos Carthami, 15 parts, Rhizoma Curcumae Longae, 10 parts of Radix Cynanchi Paniculatis, 8 parts, the Radix Rehmanniae, 10 parts of Bulbus Liliies, 10 parts of Flos Loniceraes, 6 parts, Poria, 10 parts of Fructus Lyciis, 12 parts, Herba Ephedrae, 12 parts of Rhizoma Chuanxiongs, 10 parts of the Radixs Angelicae Dahuricae, 5.5 parts of Radix Ophiopogonis, 10 parts of Rhizoma Polygoni Cuspidati, 8 parts of Caulis Spatholobis, 12 parts, Radix Glycyrrhizae.
4. the Chinese medicine composition for the treatment of acute and chronic rhinitis as claimed in claim 3, is characterized in that: described Chinese medicine composition also contains the raw material of following weight portion: 7 parts of the Radix Aucklandiae, 9 parts of 5 parts of the Cortexs Eucommiae and Radix Polygalaes.
5. the Chinese medicine composition of the treatment acute and chronic rhinitis as described in as arbitrary in claim 1-4, is characterized in that: described Chinese medicine composition is powder, water preparation, tablet or capsule.
6. prepare the method for the Chinese medicine composition for the treatment of acute and chronic rhinitis as claimed in claim 5 for one kind, it is characterized in that comprising the following steps: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, adding volumetric concentration according to 4～9 times of coarse powder gross weight is 40%～95% alcoholic solution, reflux, extract, three times, return time is 2～5h, filters, filtrate recycling ethanol, cold filtration, washes with water, after being dried, obtains Chinese medical concrete.
7. the Chinese medicine composition as described in as arbitrary in claim 1-4 is purposes in preparation treatment acute and chronic rhinitis medicine.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410113223.9A CN103861041B (en) | 2014-03-25 | 2014-03-25 | A kind of Chinese medicine composition for the treatment of acute and chronic rhinitis and preparation method thereof |
| CN201610073895.0A CN105597011A (en) | 2014-03-25 | 2014-03-25 | Method for preparing traditional Chinese medicine composition for treating acute or chronic rhinitis |
| CN201610074078.7A CN105535864A (en) | 2014-03-25 | 2014-03-25 | Application of traditional Chinese medicine composition in preparation of medicines for treating acute or chronic rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410113223.9A CN103861041B (en) | 2014-03-25 | 2014-03-25 | A kind of Chinese medicine composition for the treatment of acute and chronic rhinitis and preparation method thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610074078.7A Division CN105535864A (en) | 2014-03-25 | 2014-03-25 | Application of traditional Chinese medicine composition in preparation of medicines for treating acute or chronic rhinitis |
| CN201610073895.0A Division CN105597011A (en) | 2014-03-25 | 2014-03-25 | Method for preparing traditional Chinese medicine composition for treating acute or chronic rhinitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103861041A true CN103861041A (en) | 2014-06-18 |
| CN103861041B CN103861041B (en) | 2016-03-30 |
Family
ID=50900429
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410113223.9A Active CN103861041B (en) | 2014-03-25 | 2014-03-25 | A kind of Chinese medicine composition for the treatment of acute and chronic rhinitis and preparation method thereof |
| CN201610074078.7A Withdrawn CN105535864A (en) | 2014-03-25 | 2014-03-25 | Application of traditional Chinese medicine composition in preparation of medicines for treating acute or chronic rhinitis |
| CN201610073895.0A Withdrawn CN105597011A (en) | 2014-03-25 | 2014-03-25 | Method for preparing traditional Chinese medicine composition for treating acute or chronic rhinitis |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610074078.7A Withdrawn CN105535864A (en) | 2014-03-25 | 2014-03-25 | Application of traditional Chinese medicine composition in preparation of medicines for treating acute or chronic rhinitis |
| CN201610073895.0A Withdrawn CN105597011A (en) | 2014-03-25 | 2014-03-25 | Method for preparing traditional Chinese medicine composition for treating acute or chronic rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN103861041B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104666952A (en) * | 2015-02-15 | 2015-06-03 | 陈红 | Traditional Chinese medicine composition for treating chronic rhinitis and preparation method of traditional Chinese medicine composition |
| WO2020037592A1 (en) * | 2018-08-23 | 2020-02-27 | 王芹 | Fabric for preventing and treating cold |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1306840A (en) * | 2000-01-30 | 2001-08-08 | 刘朝兵 | Chinese medicine for treating acute and chronic rhinitis and nasosinusitis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102274395A (en) * | 2010-06-10 | 2011-12-14 | 张天良 | Traditional Chinese medicine for treating rhinitis |
-
2014
- 2014-03-25 CN CN201410113223.9A patent/CN103861041B/en active Active
- 2014-03-25 CN CN201610074078.7A patent/CN105535864A/en not_active Withdrawn
- 2014-03-25 CN CN201610073895.0A patent/CN105597011A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1306840A (en) * | 2000-01-30 | 2001-08-08 | 刘朝兵 | Chinese medicine for treating acute and chronic rhinitis and nasosinusitis |
Non-Patent Citations (1)
| Title |
|---|
| 夏锦平: "鼻窦炎中医用药规律探讨", 《中国中西医结合耳鼻咽喉科杂志》, vol. 2, no. 1, 31 December 1994 (1994-12-31), pages 33 - 34 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104666952A (en) * | 2015-02-15 | 2015-06-03 | 陈红 | Traditional Chinese medicine composition for treating chronic rhinitis and preparation method of traditional Chinese medicine composition |
| CN104666952B (en) * | 2015-02-15 | 2016-03-02 | 侯明月 | A kind of Chinese medicine composition for the treatment of chronic rhinitis and preparation method thereof |
| WO2020037592A1 (en) * | 2018-08-23 | 2020-02-27 | 王芹 | Fabric for preventing and treating cold |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103861041B (en) | 2016-03-30 |
| CN105597011A (en) | 2016-05-25 |
| CN105535864A (en) | 2016-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520497B (en) | Chinese medicinal composition for treating gout and preparation method thereof | |
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN101972338A (en) | Chinese medicinal preparation for treating infantile upper respiratory tract infection and preparation method thereof | |
| CN103041257B (en) | Chinese materia medica preparation for curing high fever and respiratory tract infection of children | |
| CN104306659A (en) | Traditional Chinese medicine composition for treating type 2 diabetes | |
| CN103861041B (en) | A kind of Chinese medicine composition for the treatment of acute and chronic rhinitis and preparation method thereof | |
| CN104825821A (en) | Medicine for treating diabetes and preparation method thereof | |
| CN104042925A (en) | Traditional Chinese medicinal composition for treating gout and preparation method thereof | |
| CN104189784A (en) | Traditional Chinese medicine preparation for aphtha and preparation method of traditional Chinese medicine preparation | |
| CN104056242A (en) | Traditional Chinese medicine composition for treating acute cholecystitis and preparation method thereof | |
| CN103989762B (en) | Chinese medicine composition of internal organs relieving cough and resolving phlegm and preparation method thereof is rushed down in a kind of heat clearing away | |
| CN104027652B (en) | A kind of hypoglycemic Chinese medicine prepn and preparation method thereof | |
| CN103550739B (en) | Traditional Chinese medicinal composition for treating acute enteritis and preparation method of traditional Chinese medicinal composition | |
| CN103463449A (en) | Traditional Chinese medicine composite used for treating haemorrhoids and preparation method and application thereof | |
| CN103751757A (en) | Traditional Chinese medicine composition for treating acute nephritis and preparation method thereof | |
| CN103705860A (en) | Traditional Chinese medicine composition for treating infant jaundice and preparation method thereof | |
| CN103041320B (en) | Traditional Chinese medicine composition for treating cervical spondylosis and preparation method thereof | |
| CN103768570B (en) | A kind of Chinese medicine composition for the treatment of acute cholecystitis and preparation method thereof | |
| CN104800288A (en) | Traditional Chinese medicine for treating acute viral pharyngitis | |
| CN101401881B (en) | Chinese medicinal composition for treating poison produced by venomous insects | |
| CN105770445A (en) | Chinese herba preparation for treating chronic atrophic gastritis and preparation method thereof | |
| CN106376928A (en) | Method for preparing compound dendrobium officinale health product assisting in reducing blood sugar | |
| CN105267687A (en) | Traditional Chinese medicine preparation for treating acute tonsillitis and preparation method thereof | |
| CN103800877A (en) | Traditional Chinese and western medicinal compound preparation for treating acute gastroenteritis and preparation method thereof | |
| CN104491537A (en) | Traditional Chinese medicine composition for treating rheumatic heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160303 Address after: Twenty-seventh, No. 396, Emei Mountain Road, Huangdao District, Shandong City, Qingdao Province, Qingdao 266555, Optics Valley Software Park, second floors Applicant after: QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO., LTD. Applicant after: Xing Weina Address before: 266200, No. seven, 179 village, Wenquan Town, Jimo, Shandong, Qingdao Applicant before: Cui Xinming |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160713 Address after: Twenty-seventh, No. 396, Emei Mountain Road, Huangdao District, Shandong City, Qingdao Province, Qingdao 266555, Optics Valley Software Park, second floors Patentee after: QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO., LTD. Address before: Twenty-seventh, No. 396, Emei Mountain Road, Huangdao District, Shandong City, Qingdao Province, Qingdao 266555, Optics Valley Software Park, second floors Patentee before: QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO., LTD. Patentee before: Xing Weina |
|
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xing Weina Inventor after: Ji Rifeng Inventor after: Wu Shaoqin Inventor after: Zhang Fucai Inventor after: Liu Shaojuan Inventor before: Xing Weina |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170525 Address after: 226200 No. 46 Industrial Park, Nanyang Town, Nantong, Jiangsu, Qidong Patentee after: Qidong planting valve factory Address before: Twenty-seventh, No. 396, Emei Mountain Road, Huangdao District, Shandong City, Qingdao Province, Qingdao 266555, Optics Valley Software Park, second floors Patentee before: QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO., LTD. |